We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Aetna Be Acquired by CVS Health to Rest Speculations?
Read MoreHide Full Article
Rumors are rife that CVS Health Corp. CVS is in advanced stages to acquire the health insurer Aetna Inc. for $66 billion.
Pharmacy benefit managers work primarily for insurers and employers and seek to negotiate the drug prices with pharmaceutical companies and drugstores to reduce the pocket-pinch for consumers. This in turn lowers the medical cost for insurers.
This news drove the shares of Aetna to a new 52-week high of $192.37. The stock has surged 45% year to date, in line with the industry's growth.
We believe, this deal has a greater probability of getting a nod from the regulators since it will be a vertical integration as compared to the horizontal combination (which was feared to create a monopoly in the market and stifle healthy competition among rivals, if passed through) of Aetna-Humana deal, which was blocked earlier in the year.
The deal seems a good complement, given that it would lead to a deadly combination of Aetna’s strong position and its expertise in the health benefits space with CVS’ deep knowledge of the consumers and its leading position in the pharmacy benefits market.
This combined entity would create a mammoth healthcare set-up with wide-ranging operations from sale of drug to insurance cover.
What’s in the Offing for Aetna?
The deal will add to Aetna’s scale and size and equip it to negotiate with drug manufacturers and pharmacies better. This would as a result lower the cost of acquiring prescription drugs, enabling the company to share the savings in with its consumers by way of more customer-friendly insurance plans like enhanced frills or lower premium, thus ultimately leading to market-share gain.
Consolidation in the Health Care Space
Mergers and acquisition (both horizontal and vertical) in the space is rife, given the necessity of the players to gain in scale and size to weather the changes taking place within the industry. Such deals (pharmacy benefit managers with insurance companies) are the need of the hour at the backdrop of a changing industry, which is rapidly seeing a rise in consumerism.
Also, the increased incidence of specialty drugs that are paid through medical and not pharmacy benefit organizations, necessitates the coming together of medical and pharmacy benefit companies.
The takeover of Catamaran by UnitedHealth Group Inc. (UNH - Free Report) also falls under this category.
Triple-S Management pulled off positive surprises in two of the trailing four quarters with an average beat of 74%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits. Click here to see the 5 stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Aetna Be Acquired by CVS Health to Rest Speculations?
Rumors are rife that CVS Health Corp. CVS is in advanced stages to acquire the health insurer Aetna Inc. for $66 billion.
Pharmacy benefit managers work primarily for insurers and employers and seek to negotiate the drug prices with pharmaceutical companies and drugstores to reduce the pocket-pinch for consumers. This in turn lowers the medical cost for insurers.
This news drove the shares of Aetna to a new 52-week high of $192.37. The stock has surged 45% year to date, in line with the industry's growth.
We believe, this deal has a greater probability of getting a nod from the regulators since it will be a vertical integration as compared to the horizontal combination (which was feared to create a monopoly in the market and stifle healthy competition among rivals, if passed through) of Aetna-Humana deal, which was blocked earlier in the year.
The deal seems a good complement, given that it would lead to a deadly combination of Aetna’s strong position and its expertise in the health benefits space with CVS’ deep knowledge of the consumers and its leading position in the pharmacy benefits market.
This combined entity would create a mammoth healthcare set-up with wide-ranging operations from sale of drug to insurance cover.
What’s in the Offing for Aetna?
The deal will add to Aetna’s scale and size and equip it to negotiate with drug manufacturers and pharmacies better. This would as a result lower the cost of acquiring prescription drugs, enabling the company to share the savings in with its consumers by way of more customer-friendly insurance plans like enhanced frills or lower premium, thus ultimately leading to market-share gain.
Consolidation in the Health Care Space
Mergers and acquisition (both horizontal and vertical) in the space is rife, given the necessity of the players to gain in scale and size to weather the changes taking place within the industry. Such deals (pharmacy benefit managers with insurance companies) are the need of the hour at the backdrop of a changing industry, which is rapidly seeing a rise in consumerism.
Also, the increased incidence of specialty drugs that are paid through medical and not pharmacy benefit organizations, necessitates the coming together of medical and pharmacy benefit companies.
The takeover of Catamaran by UnitedHealth Group Inc. (UNH - Free Report) also falls under this category.
Zacks Rank and Stocks to Consider
Aetna carries a Zacks Rank #3 (Hold). A better-ranked stocks in the same space is Triple-S Management Corp. carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Triple-S Management pulled off positive surprises in two of the trailing four quarters with an average beat of 74%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>